NewsHK
Against the backdrop of sustained pharmaceutical investment in successive nucleic acid formats, Eli Lilly (LLY) has agreed with Amplitude to develop trans-amplifying RNA vaccines.
The deal plants Lilly's flag in a platform technology that large-cap pharma has been circling for several years.
Trans-amplifying RNA is a distinct format from the conventional messenger RNA technology behind the first wave of approved vaccines. The agreement disclosed no financial terms, timelines, or indication targets.
The read-through for pharma capital allocation is clear enough. Major drug makers at Lilly's scale entering new RNA platform agreements signals that the sector's investment cycle in nucleic acid medicine has not turned.
Keep reading